Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 59.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,279 shares of the company’s stock after selling 57,074 shares during the quarter. Hillsdale Investment Management Inc. owned about 0.08% of Amphastar Pharmaceuticals worth $1,725,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in AMPH. American Century Companies Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 52.2% in the 3rd quarter. American Century Companies Inc. now owns 200,277 shares of the company’s stock worth $9,211,000 after purchasing an additional 68,668 shares during the period. Advisor Resource Council acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $814,000. Legato Capital Management LLC grew its position in shares of Amphastar Pharmaceuticals by 95.4% in the 4th quarter. Legato Capital Management LLC now owns 15,217 shares of the company’s stock worth $941,000 after acquiring an additional 7,431 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Amphastar Pharmaceuticals by 75.7% in the 4th quarter. Raymond James & Associates now owns 92,659 shares of the company’s stock worth $5,731,000 after purchasing an additional 39,916 shares during the last quarter. Finally, McGlone Suttner Wealth Management Inc. bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $28,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Trading Up 2.7 %

Shares of AMPH stock traded up $1.06 during trading hours on Monday, reaching $40.67. The company had a trading volume of 331,850 shares, compared to its average volume of 416,936. The company has a 50 day moving average of $40.63 and a 200 day moving average of $45.43. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 0.70 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.20. The firm had revenue of $171.84 million during the quarter, compared to analysts’ expectations of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. On average, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.6 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AMPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $71.00 price target on shares of Amphastar Pharmaceuticals in a research report on Thursday, June 27th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $66.00.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total transaction of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares in the company, valued at $3,246,132.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the transaction, the director now directly owns 78,409 shares of the company’s stock, valued at $3,246,132.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William J. Peters sold 3,596 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at $3,851,635.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,596 shares of company stock worth $313,544. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.